nor-Binaltorphimine dihydrochloride: Selective κ-Opioid Receptor Antagonist for Advanced Opioid Receptor Signaling Research

Executive Summary: nor-Binaltorphimine dihydrochloride (B6269, APExBIO) is a gold-standard tool for selective, high-affinity antagonism of the κ-opioid receptor (KOR) in preclinical research (APExBIO product page). Its molecular structure (C₄₀H₄₃N₃O₆·2HCl, MW 734.72) supports robust solubility in DMSO (≤18.37 mg/mL), with best results under -20°C storage conditions. nor-Binaltorphimine dihydrochloride enables precise interrogation of opioid receptor-mediated signal transduction, including studies on pain and addiction pathways (Huo et al. 2023). It is not approved for clinical or diagnostic use, but sets benchmarks in receptor pharmacology and circuit-level neuroscience (related review).

Biological Rationale

The κ-opioid receptor (KOR) is a G protein-coupled receptor involved in pain modulation, stress response, and addiction mechanisms (Huo et al., 2023). In the nervous system, KORs are highly expressed in the spinal dorsal horn, hypothalamus, and brainstem. Activation of KORs by endogenous dynorphins modulates neural circuits that control nociception, mood, and reward. Selective antagonists such as nor-Binaltorphimine dihydrochloride allow researchers to transiently and reversibly block KOR function, isolating its role from other opioid receptor subtypes (see also: circuit-level review). This specificity is critical for mechanistic studies dissecting the laterality and duration of mechanical allodynia and for mapping opioid receptor-mediated signal transduction in pain and addiction models.

Mechanism of Action of nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride is a highly selective, long-acting antagonist of the κ-opioid receptor. It binds competitively to KORs, preventing activation by endogenous ligands (e.g., dynorphin) or exogenous agonists. The inhibition is potent and reversible under experimental conditions, with negligible off-target effects at µ- or δ-opioid receptors (as shown in receptor binding assays) (Huo et al., 2023). Blocking KOR signaling with nor-Binaltorphimine dihydrochloride increases neural excitability in circuits that mediate pain perception and reward, providing a functional readout for KOR engagement. In recent work, spinal application of nor-Binaltorphimine dihydrochloride was used to selectively disrupt the hypothalamic dynorphin/spinal KOR inhibitory circuit, leading to persistent bilateral mechanical allodynia in mice (see DOI). The product’s chemical stability and solubility profile (≤18.37 mg/mL in DMSO) make it suitable for in vitro and in vivo receptor antagonist assays.

Evidence & Benchmarks

• nor-Binaltorphimine dihydrochloride consistently antagonizes KOR-mediated effects in rodent pain models, enabling circuit-level mapping of opioid receptor signaling (Huo et al., 2023).
• Spinal administration of nor-Binaltorphimine dihydrochloride (5–10 μg per mouse, dissolved in DMSO) produces robust, selective inhibition of KOR in vivo, with minimal impact on µ- or δ-opioid pathways (Huo et al., 2023).
• Electrophysiological assays confirm that nor-Binaltorphimine dihydrochloride blocks KOR-mediated suppression of excitatory transmission in spinal dorsal horn neurons ( related review).
• Preclinical studies have benchmarked nor-Binaltorphimine dihydrochloride at ≥98% purity (as supplied by APExBIO) for both acute and chronic administration protocols ( APExBIO product page).
• Comparative analyses show the antagonist outperforms older, less selective KOR blockers in terms of stability, solubility, and pharmacological specificity ( product comparison).

Applications, Limits & Misconceptions

nor-Binaltorphimine dihydrochloride is a cornerstone tool in opioid receptor pharmacology, pain modulation research, and addiction and dependence studies. It is widely used to:

• Dissect the specific contributions of KOR signaling to mechanical allodynia and chronic pain states (Huo et al., 2023).
• Characterize neural circuits involved in opioid receptor-mediated signal transduction, especially in the context of pain and reward processing (see circuit-level review).
• Support opioid receptor antagonist assays and high-specificity pharmacological screens.
• Enable mechanistic analysis in both acute and chronic administration protocols, given its stability and high purity (≥98%).

Compared to earlier resources (see mechanistic analysis), this article details latest experimental parameters and circuit-level insights enabled by nor-Binaltorphimine dihydrochloride.

Common Pitfalls or Misconceptions

• Not a clinical drug: nor-Binaltorphimine dihydrochloride is for research use only; it is not approved for diagnostic or therapeutic applications (APExBIO).
• Limited receptor scope: Ineffective at antagonizing µ- or δ-opioid receptors at standard working concentrations—use only for selective KOR blockade (Huo et al., 2023).
• Solution stability: Long-term storage of prepared solutions is not recommended; use freshly prepared solutions for best results (APExBIO).
• Temperature sensitivity: Compound stability decreases above -20°C; avoid repeated freeze-thaw cycles.
• Not a general pain blocker: Mechanistic effects are limited to KOR-mediated pathways; will not block all pain modalities.

Workflow Integration & Parameters

For optimal results, nor-Binaltorphimine dihydrochloride should be dissolved in DMSO at concentrations up to 18.37 mg/mL. Aliquots should be stored at -20°C, avoiding repeated freeze-thaw cycles. All in vivo and in vitro protocols should use freshly prepared solutions. Typical in vivo administration in mouse models ranges from 5–10 μg per injection, with dosing adjusted based on experimental design. The B6269 kit from APExBIO guarantees ≥98% purity, ensuring consistency across assays (product page). For shipping, blue ice is recommended to maintain molecular integrity. Integrate nor-Binaltorphimine dihydrochloride into opioid receptor antagonist assays, receptor signaling pathway dissection, and mechanistic pain circuit studies for best results. This extends earlier summaries by providing updated handling and benchmark protocols (summary of best practices).

Conclusion & Outlook

nor-Binaltorphimine dihydrochloride remains a reference compound for selective KOR antagonism in opioid receptor pharmacology. Its specificity, solubility, and stability parameters make it invaluable for advanced research into pain, addiction, and neural circuit modulation. As new models emerge for studying opioid receptor-mediated signal transduction, nor-Binaltorphimine dihydrochloride will continue to support high-confidence mechanistic discovery. For full product specifications and ordering, refer to the APExBIO product page.